PADRAIC

PADRAIC 4: Glucagon-like peptide-1 receptor agonists for the treatment of obesity and cancer risk: systematic review and Bayesian meta-analysis

We performed a systematic review to identify randomised controlled trials (RCTs) of liraglutide (3.0mg) or semaglutide (2.4mg) reporting interventions for weight loss in non-diabetes individuals with EBW that reported cancer and/or neoplastic (including benign tumours) events, as our two primary outcome measures. We assessed study quality using the Cochrane ROB tool. We used frequentist and Bayesian meta-analysis methods to derive summary risk estimates (expressed as relative risk, RR) and probabilities of cancer risk, respectively. We performed a priori clinically relevant sub-group analysis and meta-regression in accordance with the protocol registered with PROSPERO (CRD42024551124).